Patients undergoing catheter ablation for atrial fibrillation (AF) often experience recurrent arrhythmias within the first few months post-ablation. We aimed to investigate whether short-term use of amiodarone to prevent early arrhythmias following radiofrequency ablation for AF could reduce later recurrence.
Introduction
Patients undergoing ablation for atrial fibrillation (AF) often experience atrial tachyarrhythmias within the first few months postablation. Early recurrence of atrial arrhythmias has been associated with later recurrence following AF ablation. 1, 2 In accordance with the concept that 'AF begets AF', 3 reducing AF burden early after ablation could potentially improve the long-term effect of ablation. Amiodarone is considered the most effective antiarrhythmic drug (AAD) for rhythm control of AF. 4 Whether short-term use of amiodarone used to prevent early arrhythmias can affect later recurrence after catheter ablation for AF is unclear. We aimed to investigate, in a randomized, placebo-controlled, double-blind clinical trial, whether short-term use of amiodarone following radiofrequency ablation for AF could reduce later recurrence.
Methods

Study design
The trial was designed as a double-blind, randomized, placebo-controlled trial. The study was investigator initiated, and the manufacturer of amiodarone did not take part in the design of the study, delivery of study medication, or give any financial support. Patients referred to Rigshospitalet or Gentofte Hospital (Copenhagen University, Denmark) for ablation of AF were screened for inclusion. Patients with paroxysmal or persistent AF undergoing first time or repeat ablation were eligible for inclusion. Exclusion criteria were age ,18 years, contraindications to or previous side effects during oral amiodarone therapy, amiodarone therapy within 3 months before the ablation procedure, sustained AF .1 year, other atrial arrhythmias than AF and typical atrial flutter, severe heart failure (New York Heart Association class III, IV, or LVEF ,35%), significant heart valve disease, previous participating in the study, thyroid disease, severe pulmonary or liver disease, and woman with child bearing potential.
The trial was conducted in accordance with the Helsinki Declaration and was approved by the Danish Regional Ethics Committee, the Danish Medicines Agency, and the Danish Data Protection Agency. The trial was registered at ClinicalTrial.gov prior to study start (NCT00826826), and it was monitored by the regional Good Clinical Practice unit. Written informed consent was obtained from all participants prior to inclusion. Enrolment began in February 2009 at Rigshospitalet, in January 2011 at Gentofte Hospital, and was terminated in July 2013. Follow-up was finalized in January 2014.
Ablation, randomization, and study treatment
Patients underwent transthoracic echocardiography before the ablation and no longer than 3 months prior to the ablation procedure. Thoracic X-ray, thyroid, and liver parameters were tested within 3 days before ablation to reveal possible exclusion criteria. All patients underwent transoesophageal echocardiography within 48 h of the ablation and were on continuous oral anticoagulation (OAC) with a vitamin K antagonist for at least 4 weeks pre-ablation and 3 months post-ablation.
All patients underwent pulmonary vein (PV) isolation by radiofrequency ablation. A three-dimensional mapping system was used in all patients (NavX or CARTO). Procedural end-point was PV isolation by wide antral circumferential ablation assessed by meticulous remapping (centre 1) or by a circular mapping catheter (centre 2). If atrial tachyarrhythmias occurred, they were mapped and ablated by standard approaches. Additional substrate modification (linear ablations or complex fractionated electrogram-guided ablations) was left to the discretion of the operating electrophysiologist. Complex fractionated electrogram-guided ablations were considered in patients with longer lasting persistent AF (i.e. patients with episodes of persistent AF lasting for months) or targeted if electrical cardioversion failed following PV isolation. A fairly conservative strategy for additional ablations was followed. Cavotricuspid isthmus block was performed in patients with documented typical atrial flutter. Patients undergoing re-ablation where the PVs were found already isolated were not randomized in the study. Each patient only underwent a single ablation procedure during their participation in the trial.
Following ablation, patients were stratified according to the type of AF (paroxysmal/persistent) in compliance with international definitions, 5 history of previous AF ablation, and hospital of the ablation procedure and randomly assigned to 8 weeks of oral amiodarone therapy or matched placebo in blocks of eight. The loading regimen was inspired from the EMIAT trial. 6 Amiodarone was initiated on the night of the ablation with a dose of 400 mg, thereafter 400 mg twice daily for 13 days, then 200 mg twice daily for 2 weeks and finally 200 mg once daily for 4 weeks. Patients weighing ,60 kg were individually dosed.
Other antiarrhythmic medications were discontinued 3-5 days before ablation except rate controlling medication given for other indications (e.g. hypertension, ischaemic heart disease, and systolic dysfunction). Rate controlling medication could be started within the study-medication period if needed.
Patient follow-up
Patients were discharged from hospital the day after the ablation procedure and OAC was continued for at least 3 months. Any change from vitamin K antagonist to novel OAC could be made no earlier than 3 months post-ablation. Patients' OAC was handled and monitored by their local OAC clinic or by their general physician and the patients were carefully instructed to have their international normalized ratio (INR) measured once or twice a week for the first 4 weeks following ablation for potential dose-adjustments due to drug interactions and thereafter as necessary. Study visits were scheduled before randomization and at 1, 3, and 6 months. Each visit comprised detailed history, a routine physical examination, 12-lead electrocardiography (ECG), blood pressure measurement, and laboratory testing. A 3-day Holter-monitoring was performed before ablation, at 6-8 weeks and at the 6-month follow-up. With each Holtermonitoring, the patients completed questionnaires regarding quality of life [including Short Form 36 Health Survey (SF-36), version 1]. Patients were encouraged to register all arrhythmia-related symptoms and, especially after the blanking period, have an ECG taken during symptoms. In case of longer lasting arrhythmia symptoms, patients were instructed to contact us or their local hospital to allow cardioversion within 48 h. If a patient experienced arrhythmia symptoms and could not be monitored during an acute episode, additional monitoring (e.g. extra Holter or event monitoring) was performed. All ECGs and Holter-monitorings were reviewed by a study investigator.
If patients had started antiarrhythmic medication (class 1C or III) other than the study medication within the blanking period, they were encouraged to discontinue this at the end of the 3-month blanking period. Patients with abnormal laboratory testing parameters (e.g. thyroid parameters) were conferred with the relevant specialties and patients with QTc .550 ms during follow-up had their study medication discontinued (pre-specified in the protocol).
Primary and secondary outcomes
The primary end-point of the trial was any documented atrial tachyarrhythmia (AF, atrial flutter or atrial tachycardia [AF/AT]) lasting .30 s following a blanking period of 3 months. Secondary end-points included time to first documented AF/AT and number of AF/AT-related hospital admissions and cardioversions (direct current and medical cardioversions) within the blanking period. Additional secondary end-points included the need for rate controlling medication within the blanking period and quality of life and adverse events throughout the study. All cardiac rhythm recordings concerning the primary outcome were evaluated by an adjudication committee before unblinding the trial.
Patients who were re-ablated within the blanking period due to recurrent, refractory atrial tachyarrhythmias uncontrollable with antiarrhythmic medication and cardioversions were considered as recurrences in the analysis of the primary end-point, even though these events occurred within blanking period.
Short-term amiodarone after catheter ablation for atrial fibrillation (AMIO-CAT trial) Statistics A power calculation was performed prior to study start. To reveal a 50% reduction in an expected recurrence rate of 40% after a single ablation procedure, we calculated the need for a minimum of 182 patients (power of 80% and type I error probability of 0.05) to be randomized in the study.
Analyses were performed according to the intention-to-treat principle. Proportions of patients with recurrence at the 6-month follow-up in the amiodarone group and the placebo group were compared using x 2 test. Quasi-Poisson regression 7 was used to assess the number of AF/AT-related hospitalizations and cardioversions. Time to first documented recurrence within the blanking period was analysed by the log-rank statistic and plotted using Kaplan -Meier survival curves (there were no competing events). To assess possible predictors for recurrence at the 6-month follow-up, we used a logistic regression model. Prespecified relevant clinical characteristics were tested first in a univariate and then in a multivariate-adjusted model. Comparison of quality of life was performed using independent samples and paired samples t-test. Continuous data are reported as means (+SD) or medians (interquartile range [IQR] ) and comparisons between groups were performed with the use of Student's t-test or Wilcoxon-Mann-Whitney test where appropriate. Categorical data were reported as proportions or percentages and comparisons between groups were performed using x 2 test or Fisher's exact test where appropriate. Statistical tests were two-tailed, and P , 0.05 was considered statistically significant. Analyses were conducted using SPSS version 19.0 (IBM Corp., Armonk, NY) and R (R Foundation for Statistical Computing, Vienna, Austria; http://www.R-project.org/). Patients who were lost to follow-up or died before completing the 6-month follow-up visit were excluded from the analysis of the primary end-point. All randomized patients were included in analyses comparing AF/AT-related hospitalizations, cardioversions, and time to first recurrence within the blanking period.
Results
Population
A total of 1293 patients referred for AF ablation at the participating hospitals were screened for enrolment. In total, 254 patients were included and 212 underwent randomization ( Figure 1 ). We randomly assigned 108 patients to the amiodarone group and 104 to the placebo group. There were no significant differences in baseline characteristics or ablation procedural characteristics between the two groups ( Tables 1 and 2 ). Patients were followed for a median of 190 days .
Five patients were lost to follow-up during the blanking period and one patient died from ischaemic stroke (see Figure 1 for details). Two patients (one in each of the randomization groups) undergoing re-ablation were randomized in error (PVs were found already isolated and the patients had other ectopic atrial foci than the PVs) but were included in the analyses in accordance with the intention-to-treat principle. Four patients undergoing first ablation (all in the placebo group) were re-ablated within the blanking period due to recurrent, refractory atrial tachyarrhythmias.
Fifteen patients (14%) in the placebo group and 10 (9%) in the amiodarone group discontinued the study medication prematurely (P ¼ 0.24): eight patients to start open amiodarone (5 vs. 3), three patients to start other AAD (2 vs. 1), seven patients due to side effects (2 vs. 5), four patients because they were re-ablated within 8 weeks from randomization (4 vs. 0), two because they left/were excluded from the trial (2 vs. 0), and one because of QTc interval .550 ms (amiodarone group). The randomization code was broken for 5/104 (5%) patients in the placebo group and 1/108 (1%) in the amiodarone group, all for the reason of starting amiodarone or sotalol.
Primary end-point
In total, 206 patients completed the last patient visit and were available for analysis of the primary end-point. At the 6-month follow-up, 48/99 (48%) patients in the placebo group and 42/107 (39%) patients in the amiodarone group had had a documented (symptomatic or asymptomatic) episode of AF or AT . 30 s. This difference was not statistically significant (P ¼ 0.18) ( Figure 2 ). All patients without documented AF/AT at the 6-month follow-up had completed the final 3-day Holter-monitoring and were off AAD, except for one patient in the amiodarone group who was unwilling to stop 'open' amiodarone initiated during the blanking period. Noteworthy, 11 (12%) of the 90 patients with recurrence had asymptomatic AF/AT at their first documented event after the blanking period (7/48, 15% in the placebo group and 4/42, 10% in the amiodarone group, respectively, P ¼ 0.45).
Follow-up within the blanking period
Amiodarone significantly reduced the number of patients with documented recurrence within the 3-month blanking period compared with placebo (37/108, 34% vs. 55/104, 53%, P ¼ 0.006). Time to first documented incidence of AF/AT . 30 s within the blanking period was plotted using the Kaplan-Meier method (Figure 3) . When analysing patients in subgroups of paroxysmal (n ¼ 107) and persistent (n ¼ 105) AF, time to first documented incidence of AF/AT was still significantly longer for the amiodarone group (Log rank, P ¼ 0.045 and P ¼ 0.005, respectively). During the blanking period, there were 152 AF/AT-related hospitalizations in 68/212 (32%) patients. The rate of AF/AT-related hospitalizations was significantly lower in the amiodarone group compared with placebo ( Figure 4) . A total of 145 cardioversions were performed in 68/212 (32%) patients during the blanking period. The rate of cardioversions (direct current or medical cardioversion) (145 in total) was also significantly lower in the amiodarone group compared with placebo ( Figure 4) . In a subgroup analysis, dividing patients into paroxysmal (n ¼ 107) and persistent (n ¼ 105) AF, we still found the rates of hospitalizations and cardioversions to be significantly lower in the amiodarone-treated patients with persistent AF. This, however, was not the case for patients with paroxysmal AF. The rate ratios are displayed for the subgroups during the blanking period and the total study period in Figure 4 .
Significantly more patients in the placebo group started rate controlling medication (b-blocker, digoxin, or calcium channel blocker) during the blanking period compared with the amiodarone group (34/104, 33% vs. 19/108, 18%, P ¼ 0.009). There was no significant difference in the number of patients who started an AAD (class 1C or III) during the blanking period (11/104, 11% in the placebo group vs. 6/108, 5% in the amiodarone group, P ¼ 0.17).
Six-month follow-up
Significantly more patients with recurrence of AF/AT at the 6-month follow-up had had a documented episode of AF/AT during the blanking period compared with those without recurrence (61/90, Previous ablation for typical flutter or planned cavotricuspid isthmus block at this ablation.
68% vs. 27/116, 23%, respectively, P , 0.001). To assess possible predictors for recurrence at the 6-month follow-up, we first tested pre-specified relevant variables (age, gender, AF duration, left atrial diameter, history of persistent AF, history of previous ablation, documented AF/AT during the blanking period and hospitalization, or cardioversion within blanking period) in a univariate model. Only documented AF/AT [odds ratio (OR) 6.9; 95% confidence interval (CI) 3.7 -12.9, P , 0.001] and hospitalization or cardioversion (OR ¼ 3.8; 95% CI ¼ 2.1 -7.1, P , 0.001) during the blanking period were found statistically significantly associated with recurrence at the 6-month follow-up. When tested in a multivariate model containing all pre-specified variables, only documented AF/AT (OR ¼ 13.1; 95% CI ¼ 3.9 -43.6, P , 0.001) within the blanking period was found to be statistically significantly associated with recurrence at the 6-month follow-up.
Side effects, adverse events, and quality of life
Six patients (3%) had possible complications to the ablation procedure: one patient had a transient ischaemic attack during the ablation procedure (amiodarone group), one had an accidental femoral artery puncture and pseudo aneurism (placebo group), and four patients (two from each treatment group) had prolongation of their hospital stay due to infection/fever. Seven patients (3%) discontinued the study medication prematurely due to side effects. Four patients (4%) in the amiodarone group and none (0%) in the placebo group had a hospitalization due to high INR (P ¼ 0.12). By Holter-monitoring and 12-lead ECG during follow-up, we found two patients in the placebo group with asymptomatic episodes of 28AV-block type II, one patient in the amiodarone group with asymptomatic nodal rhythm and one patient in the amiodarone group with symptomatic bradycardia and sinoatrial block up to 5.5 s (no syncope), but none were statistically significant. More patients in the amiodarone group experienced sleep disturbances (16/108, 15 vs. 1/104, 1%, P , 0.001), gastrointestinal symptoms (26/108, 24 vs. 7/104, 7%, P , 0.001), photosensitivity (6/108, 6 vs. 0, 0%; P ¼ 0.03) or had (asymptomatic) abnormal thyroid parameters (27/108, 26 vs. 5/104, 5%, P , 0.001). Only one Short-term amiodarone after catheter ablation for atrial fibrillation (AMIO-CAT trial) patient (placebo group) required anti-thyroid medication for hyperthyroidism during the study. We found no significant difference in the number of patients with serious adverse events (19/104, 18% for placebo vs. 26/108, 24% for amiodarone, P ¼ 0.30). No patients were suspected of having pulmonary toxicity.
Quality of life was assessed with SF-36 at baseline, at 8 weeks and at the 6-month follow-up. We found no statistically significant differences in physical or mental component scores (PCS and MCS) between the placebo and the amiodarone group at baseline at 8 weeks or at 6 months ( Table 3) . For patients in both groups, PCS and MCS improved significantly over time (Table 3) ; however, there were no significant differences in the improvements between the two treatment groups.
Discussion
This study is the first double-blind randomized clinical trial to evaluate whether short-term oral amiodarone treatment given to prevent early recurrence following radiofrequency ablation for AF can reduce later recurrence. We found that, during a 3-month blanking period, amiodarone significantly prolonged time to first recurrence and more than halved arrhythmia-related hospitalization and cardioversion rates. Regardless of these findings, amiodarone did not significantly reduce the primary end-point, i.e. recurrence of AF/AT at the 6-month follow-up. Early recurrence of AF/AT within the first few months following ablation for AF is common, 8, 9 and AADs are frequently used within this period. The clinical significance of these early arrhythmias and the possible effect of AADs, however, remains unclear. 10 A few other studies with similarities to this study have also found that AADs reduce recurrences within the blanking period. Roux et al.
11
found that empirical use of AADs during the first 6 weeks following ablation for paroxysmal AF (100 patients) significantly reduced a composite end-point including clinically significant arrhythmias and the need for hospitalization or cardioversion within the blanking period, but there was no difference in recurrence of AF/AT at the 6-month follow-up. 12 In a study investigating the effect of extensive AADs vs. one AAD in 123 patients undergoing ablation for persistent AF, Gu et al. also found significantly lower recurrence of AF/ATs in the extensive AAD group within a 2-month blanking period, but no significant difference in later recurrence at the 12-month follow-up. 13 The cardioversion (or hospitalization) rates in our study were comparable with those found in other studies.
14 Of note, when analysing patients in subgroups of paroxysmal vs. persistent AF, we found that the reduction in AF/AT-related hospitalizations and cardioversions in the amiodarone group within the blanking period were only statistically significant in the group of persistent AF. Thus, it seems that effect was largely driven by the group of patients with persistent AF. In accordance with this, Hayashi et al. 15 found no difference in recurrence within the blanking period in a group of 126 predominately paroxysmal AF patients assigned to 3 months of flecainide or control following ablation. In this study, we found that documented recurrence within the blanking period was an independent predictor of later recurrence (at 6 months). Other studies have made similar findings. 9, 12, 13 Significantly, more patients in the amiodarone group experienced adverse effects. This is comparable with other studies with shortterm and prolonged amiodarone treatment. 6, 16 Interestingly, despite a higher number of adverse events in the amiodarone group, we found no statistically significant difference in quality of life measures by PCS and MCS at 8 weeks or the 6-month follow-up. This could reflect the reduced AF/AT-related hospitalizations and cardioversions in the amiodarone group. This study demonstrates that short-term amiodarone therapy initiated at the day of ablation was safe and did not impair patients' quality of life and, although amiodarone did not affect recurrence at the 6-month follow-up, its beneficial effects in rhythm control during the blanking period demonstrated by reduced hospitalization and cardioversion rates still make it a relevant strategy after AF ablation. In addition, one might also expect that the reduced AF/AT-related hospitalization and cardioversion rates could reduce the cost of post-ablation care. Current guidelines for AF ablation do not give specific recommendations with respect to AAD therapy early after ablation. 10 Our data suggest that short-term prophylactic treatment with amiodarone should be considered following ablation, particularly for patients with persistent AF.
Limitations
As we did not perform continuous ECG monitoring but only performed planned 12 lead ECGs, 3-day Holter-monitorings, and otherwise symptom-driven cardiac rhythm monitoring, we could have missed some asymptomatic recurrences. The ablation technique was not completely uniform between the two ablation centres but since patients were stratified according to centre when randomized, it is unlikely that this would have influenced the findings between the two treatment groups. In addition, this might be more representative for every-day life in larger specialized clinics where different ablations techniques are used.
The power calculation and sample size were based on a 50% reduction of recurrence rate. Hence, a lower reduction of recurrence rate at 6 months might not be detected in this study. This decision was made with the potential side effects of amiodarone in mind.
Only 16% of the referred patients were randomized in the trial, which makes it a rather selected population. A follow-up of 6 months is relatively short and one could also argue that since amiodarone has long half-life, a lingering antiarrhythmic effect could persist beyond the blanking period and reduce recurrence at 6 months in the amiodarone group; however, since we found no statistically significant difference in recurrence at 6 months, it is unlikely that this would be any different at the 12-month follow-up.
Subgroup analyses of the primary end-point based on the type of AF (paroxysmal/persistent) and whether patients were treated with PVI only or PVI plus additional ablations might have been interesting. The latter comparison might even more accurately reflect the extent of electroanatomical remodelling of the left atria, thus provide better information on mechanisms and possible treatment success of the ablation than the clinical term paroxysmal/persistent. However, in the present setting, such subgroup analysis would be statistically underpowered and were not performed due to the risk of false-negative findings.
Conclusion
Short-term oral amiodarone treatment following ablation for paroxysmal or persistent AF did not significantly reduce recurrence of AF/ AT at the 6-month follow-up, but it prolonged time to first documented recurrence and more than halved arrhythmia-related hospitalization and cardioversion rates within the blanking period.
